Mary Kay Fenton

2016 - Achillion Pharmaceuticals

In 2016, Mary Kay Fenton earned a total compensation of $1.1M as Executive Vice President and Chief Financial Officer at Achillion Pharmaceuticals, a 112% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$101,932
Option Awards$635,350
Salary$371,000
Other$8,310
Total$1,116,592

Fenton received $635.4K in option awards, accounting for 57% of the total pay in 2016.

Fenton also received $101.9K in non-equity incentive plan, $371K in salary and $8.3K in other compensation.

Rankings

In 2016, Mary Kay Fenton's compensation ranked 7,710th out of 14,075 executives tracked by ExecPay. In other words, Fenton earned more than 45.2% of executives.

ClassificationRankingPercentile
All
7,710
out of 14,075
45th
Division
Manufacturing
2,921
out of 5,486
47th
Major group
Chemicals And Allied Products
963
out of 1,900
49th
Industry group
Drugs
747
out of 1,543
52nd
Industry
Pharmaceutical Preparations
593
out of 1,173
49th
Source: SEC filing on April 17, 2017.

Fenton's colleagues

We found four more compensation records of executives who worked with Mary Kay Fenton at Achillion Pharmaceuticals in 2016.

2016

Milind Deshpande

Achillion Pharmaceuticals

Chief Executive Officer

2016

Joel Barrish

Achillion Pharmaceuticals

Chief Scientific Officer

2016

David Apelian

Achillion Pharmaceuticals

Chief Medical Officer

2016

Joseph Truitt

Achillion Pharmaceuticals

Executive Vice President and Chief Commercial Officer

News

In-depth

You may also like